Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion type Assertion NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_head.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_provenance.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion evidence source_evidence_literature NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_provenance.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion SIO_000772 19074734 NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_provenance.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion wasDerivedFrom befree-20140225 NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_provenance.
- NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_assertion wasGeneratedBy ECO_0000203 NP468927.RAnn7gsdonpa914ulwNTcQ5ca1vFpWZW3XRRR6MlVdHNY130_provenance.